1. Home
  2. IDYA vs SOC Comparison

IDYA vs SOC Comparison

Compare IDYA & SOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • SOC
  • Stock Information
  • Founded
  • IDYA 2015
  • SOC 2020
  • Country
  • IDYA United States
  • SOC United States
  • Employees
  • IDYA N/A
  • SOC N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • SOC
  • Sector
  • IDYA Health Care
  • SOC
  • Exchange
  • IDYA Nasdaq
  • SOC Nasdaq
  • Market Cap
  • IDYA 2.0B
  • SOC 2.2B
  • IPO Year
  • IDYA 2019
  • SOC N/A
  • Fundamental
  • Price
  • IDYA $17.05
  • SOC $25.92
  • Analyst Decision
  • IDYA Strong Buy
  • SOC Buy
  • Analyst Count
  • IDYA 13
  • SOC 4
  • Target Price
  • IDYA $53.58
  • SOC $26.25
  • AVG Volume (30 Days)
  • IDYA 887.8K
  • SOC 1.3M
  • Earning Date
  • IDYA 05-06-2025
  • SOC 05-14-2025
  • Dividend Yield
  • IDYA N/A
  • SOC N/A
  • EPS Growth
  • IDYA N/A
  • SOC N/A
  • EPS
  • IDYA N/A
  • SOC N/A
  • Revenue
  • IDYA $7,000,000.00
  • SOC N/A
  • Revenue This Year
  • IDYA $89.14
  • SOC N/A
  • Revenue Next Year
  • IDYA $291.34
  • SOC N/A
  • P/E Ratio
  • IDYA N/A
  • SOC N/A
  • Revenue Growth
  • IDYA N/A
  • SOC N/A
  • 52 Week Low
  • IDYA $16.88
  • SOC $10.11
  • 52 Week High
  • IDYA $44.42
  • SOC $32.33
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 31.80
  • SOC 51.35
  • Support Level
  • IDYA $17.05
  • SOC $24.20
  • Resistance Level
  • IDYA $18.90
  • SOC $27.06
  • Average True Range (ATR)
  • IDYA 0.91
  • SOC 1.28
  • MACD
  • IDYA 0.01
  • SOC 0.16
  • Stochastic Oscillator
  • IDYA 6.27
  • SOC 75.90

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

About SOC Sable Offshore Corp. Common Stock

Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.

Share on Social Networks: